Streptococcal B vaccine conjugate - GlaxoSmithKline
Alternative Names: CRM-glycoconjugate GBS vaccine; GBS maternal vaccine; GBS Trivalent Vaccine; GBS vaccine; GBS vaccine - GlaxoSmithKline; GBS vaccine - Intercell; GBS vaccine - Valneva; Group B Streptococcus vaccine - Intercell; Group B Streptococcus vaccine - Valneva; Trivalent PG vaccine - GlaxoSmithKlineLatest Information Update: 21 Aug 2019
At a glance
- Originator Intercell
- Developer GlaxoSmithKline
- Class Conjugate vaccines; Glycoconjugates; Polysaccharides; Streptococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Streptococcal infections
Most Recent Events
- 21 Aug 2019 Discontinued - Phase-I for Streptococcal infections (Prevention, In adults) in Switzerland (IM)
- 21 Aug 2019 Discontinued - Phase-II for Streptococcal infections (In infants, In neonates, Prevention) in Canada, South Africa, Malawi, USA, Belgium (IM)
- 21 Aug 2019 Discontinued - Phase-II for Streptococcal infections (Prevention, In adults) in Belgium, USA, Belgium, Czech Republic (IM)